Diuretics, Calciuria and Secondary Hyperparathyroidism in the Chronic Renal Insufficiency Cohort

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2011 Mar 9

PMID 21382989

Citations 20

Authors

Tamara Isakova

Cheryl A M Anderson

Mary B Leonard

Dawei Xie

Orlando M Gutierrez

Leigh K Rosen

Jacquie Theurer

Keith Bellovich

Susan P Steigerwalt

Ignatius Tang

Amanda Hyre Anderson

Raymond R Townsend

Jiang He

Harold I Feldman

Myles Wolf

Affiliations

Soon will be listed here.

Abstract

Background: Secondary hyperparathyroidism is a common complication of chronic kidney disease (CKD) that is associated with bone disease, cardiovascular disease and death. Pathophysiological factors that maintain secondary hyperparathyroidism in advanced CKD are well-known, but early mechanisms of the disease that can be targeted for its primary prevention are poorly understood. Diuretics are widely used to control volume status and blood pressure in CKD patients but are also known to have important effects on renal calcium handling, which we hypothesized could alter the risk of secondary hyperparathyroidism.

Methods: We examined the relationship of diuretic treatment with urinary calcium excretion, parathyroid hormone (PTH) levels and prevalence of secondary hyperparathyroidism (PTH ≥ 65 pg/mL) in a cross-sectional study of 3616 CKD patients in the Chronic Renal Insufficiency Cohort.

Results: Compared with no diuretics, treatment with loop diuretics was independently associated with higher adjusted urinary calcium (55.0 versus 39.6 mg/day; P < 0.001), higher adjusted PTH [67.9, 95% confidence interval (CI) 65.2-70.7 pg/mL, versus 52.8, 95% CI 51.1-54.6 pg/mL, P < 0.001] and greater odds of secondary hyperparathyroidism (odds ratio 2.1; 95% CI 1.7-2.6). Thiazide monotherapy was associated with lower calciuria (25.5 versus 39.6 mg/day; P < 0.001) but only modestly lower PTH levels (50.0, 95% CI 47.8-52.3, versus 520.8, 95% CI 51.1-54.6 pg/mL, P = 0.04) compared with no diuretics. However, coadministration of thiazide and loop diuretics was associated with blunted urinary calcium (30.3 versus 55.0 mg/day; P <0.001) and odds of hyperparathyroidism (odds ratio 1.3 versus 2.1; P for interaction = 0.05) compared with loop diuretics alone.

Conclusions: Loop diuretic use was associated with greater calciuria, PTH levels and odds of secondary hyperparathyroidism compared to no treatment. These associations were attenuated in patients who were coadministered thiazides. Diuretic choice is a potentially modifiable determinant of secondary hyperparathyroidism in CKD.

Citing Articles

Influence of loop diuretics on denosumab-induced hypocalcaemia in osteoporosis: a retrospective observational analysis.

Hirai T, Mori Y, Ogura T, Kondo Y, Sakazaki Y, Ishitsuka Y J Pharm Health Care Sci. 2024; 10(1):60.

PMID: 39334301 PMC: 11437979. DOI: 10.1186/s40780-024-00380-8.

Skeletal Muscle Injury in Chronic Kidney Disease-From Histologic Changes to Molecular Mechanisms and to Novel Therapies.

Heitman K, Alexander M, Faul C Int J Mol Sci. 2024; 25(10).

PMID: 38791164 PMC: 11121428. DOI: 10.3390/ijms25105117.

Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism.

Phelps K, Gemoets D, May P PLoS One. 2022; 17(8):e0272380.

PMID: 35913960 PMC: 9342777. DOI: 10.1371/journal.pone.0272380.

Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease.

Liu J, Tio M, Verma A, Schmidt I, Ilori T, Knauf F J Clin Endocrinol Metab. 2021; 107(1):e281-e292.

PMID: 34390334 PMC: 8684460. DOI: 10.1210/clinem/dgab574.

Effects of diuretics furosemide and hydrochlorothiazide on CKD-MBD: A prospective randomized study.

Vasco R, Takayama L, Pereira R, Moyses R, Elias R Bone Rep. 2021; 14:100746.

PMID: 33490315 PMC: 7811042. DOI: 10.1016/j.bonr.2021.100746.

References

Stein M, Scherer S, Walton S, Gilbert R, Ebeling P, Flicker L . Risk factors for secondary hyperparathyroidism in a nursing home population. Clin Endocrinol (Oxf). 1996; 44(4):375-83. DOI: 10.1046/j.1365-2265.1996.701521.x. View

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G . Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16(7):2205-15. DOI: 10.1681/ASN.2005010052. View

Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H . Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007; 72(8):1004-13. DOI: 10.1038/sj.ki.5002451. View

Hagstrom E, Hellman P, Larsson T, Ingelsson E, Berglund L, Sundstrom J . Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009; 119(21):2765-71. DOI: 10.1161/CIRCULATIONAHA.108.808733. View

Gutierrez O, Mannstadt M, Isakova T, Rauh-Hain J, Tamez H, Shah A . Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359(6):584-92. PMC: 2890264. DOI: 10.1056/NEJMoa0706130. View

Reichel H, Deibert B, Geberth S, Schmidt-Gayk H, Ritz E . Frusemide therapy and intact parathyroid hormone plasma concentrations in chronic renal insufficiency. Nephrol Dial Transplant. 1992; 7(1):8-15. View

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus J, Thadhani R . Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349(5):446-56. DOI: 10.1056/NEJMoa022536. View

Bibbins-Domingo K, Chertow G, Coxson P, Moran A, Lightwood J, Pletcher M . Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010; 362(7):590-9. PMC: 3066566. DOI: 10.1056/NEJMoa0907355. View

Nickolas T, Leonard M, Shane E . Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008; 74(6):721-31. PMC: 4139042. DOI: 10.1038/ki.2008.264. View

10.

Parker B, Schurgers L, Brandenburg V, Christenson R, Vermeer C, Ketteler M . The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010; 152(10):640-8. PMC: 3079370. DOI: 10.7326/0003-4819-152-10-201005180-00004. View

11.

Subar A, Thompson F, Kipnis V, Midthune D, HURWITZ P, McNutt S . Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires : the Eating at America's Table Study. Am J Epidemiol. 2001; 154(12):1089-99. DOI: 10.1093/aje/154.12.1089. View

12.

Taylor E, Curhan G . Demographic, dietary, and urinary factors and 24-h urinary calcium excretion. Clin J Am Soc Nephrol. 2009; 4(12):1980-7. PMC: 2798871. DOI: 10.2215/CJN.02620409. View

13.

Carbone L, Johnson K, Bush A, Robbins J, Larson J, Thomas A . Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative. Arch Intern Med. 2009; 169(2):132-40. DOI: 10.1001/archinternmed.2008.526. View

14.

Rejnmark L, Vestergaard P, Mosekilde L . Fracture risk in patients treated with loop diuretics. J Intern Med. 2005; 259(1):117-24. DOI: 10.1111/j.1365-2796.2005.01585.x. View

15.

Levin A, Bakris G, Molitch M, Smulders M, Tian J, Williams L . Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2006; 71(1):31-8. DOI: 10.1038/sj.ki.5002009. View

16.

Lim L, Fink H, Blackwell T, Taylor B, Ensrud K . Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women. J Am Geriatr Soc. 2009; 57(5):855-62. PMC: 2721719. DOI: 10.1111/j.1532-5415.2009.02195.x. View

17.

Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

18.

Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T . Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010; 78(10):975-80. DOI: 10.1038/ki.2010.313. View

19.

Kovesdy C, Ahmadzadeh S, Anderson J, Kalantar-Zadeh K . Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008; 73(11):1296-302. DOI: 10.1038/ki.2008.64. View

20.

Galitzer H, Ben-Dov I, Silver J, Naveh-Many T . Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2009; 77(3):211-8. DOI: 10.1038/ki.2009.464. View